Recently, it was shown that EGFR inhibitor synergized with LXRα agonists in killing cancer cells (36); for example, LXR ligands combined with gefitinib could better suppress cell cycle progression in NSCLC cells (57, 58). Here, EGFR is linked to non-small cell lung carcinoma.